High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma - Prabadin Corp

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

$High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma$

Health

June 16, 2025

By AdminPrabadin - 2 months ago

0

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

administrator